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Pulmonary fibrosis is a severe and progressive disease that is characterized by an
abnormal deposition of extracellular matrix, such as collagens. The pathogenesis of this
disease may be initiated by oxidative damage of lung epithelial cells by fibrogenic stimuli,
leading to lung inflammation, which in turn promotes various lung fibrotic responses.
The profibrogenic effect of transforming growth factor-β1 (TGF-β1) on lung fibroblasts
is crucial for the pathogenesis of this disease. Paeonol, the main phenolic compound
present in the Chinese herb Paeonia suffruticosa, has antioxidant and anti-inflammatory
properties. However, whether paeonol has therapeutic effects against pulmonary fibrosis
remains unclear. Using a murine model, we showed that 21 days after the insult,
intratracheal bleomycin caused pulmonary inflammation and fibrosis, as evidenced by
lung histopathological manifestations and increase in various indices. The inflammatory
indices included an increase in total cell count, differential cell count, and total protein
concentration in bronchoalveolar lavage fluid. The fibrotic indices included an increase
in lung levels of TGF-β1, total collagen, type 1α1 collagen (COL1A1), and α-smooth
muscle actin (α-SMA; a marker of myofibroblasts). Bleomycin also was found to cause
an increase in oxidative stress as reflected by increased levels of malondialdehyde
and 4-hydroxynonenal in the lungs. Importantly, all these pathophysiological events
were suppressed by daily treatment with paeonol. Using human lung fibroblasts, we
further demonstrated that exposure of human lung fibroblasts to TGF-β1 increased
productions of α-SMA and COL1A1, both of which were inhibited by inhibitors of Jun
N-terminal kinase (JNK), p38, and Smad3. JNK and p38 are two subfamily members
of mitogen-activated protein kinases (MAPKs), whereas Smad3 is a transcription factor.
TGF-β1 exposure also increased the phosphorylation of JNK, p38, and Smad3 prior
to the induction of α-SMA and COL1A1. Notably, all these TGF-β1-induced cellular
events were suppressed by paeonol treatment. Our findings suggest that paeonol
has antioxidant, anti-inflammatory, and anti-fibrotic functions against bleomycin-induced
pulmonary fibrosis in mice. The beneficial effect of paeonol may be, at least in part,
mediated through the inhibition of the MAPKs/Smad3 signaling.
Keywords: paeonol, bleomycin, pulmonary inflammation, pulmonary fibrosis, collagen, α-smooth muscle actin,
mice, lung fibroblasts
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INTRODUCTION
Pulmonary fibrosis is a severe and progressive disease
associated with considerable morbidity and mortality in humans
(Hutchinson et al., 2015; Raghu et al., 2015). It is characterized by
destruction of alveolar structures with an abnormal deposition
of extracellular matrix, such as collagen (Wilson and Wynn,
2009; Wuyts et al., 2013). The etiology of pulmonary fibrosis
varies, and this disease has an array of triggers, including
chemicals, radiation, fibrogenic environmental toxins, or other
unknown factors (Wilson and Wynn, 2009). The development
of pulmonary fibrosis involves sequential events, including
injury, inflammation, and repair, and dysregulation at one or
more of these events is essential for its pathogenesis (Wilson
and Wynn, 2009; Wuyts et al., 2013). Oxidative stress may be
one factor that participates in the initiation and progression of
these events (Cheresh et al., 2013). Thus, the pathogenesis of this
disease may be initiated by damage of lung epithelial cells by
fibrogenic stimuli, thereby leading to lung inflammation, which
is regulated by various types of cells and cytokines (Cheresh
et al., 2013; Wuyts et al., 2013). To this end, transforming
growth factor-β1 (TGF-β1) is the most potent profibrogenic
cytokine (Wuyts et al., 2013). TGF-β1 can directly stimulate
lung fibroblasts to secrete collagens or induce transformation of
fibroblasts to myofibroblasts that express α-smooth muscle actin
(α-SMA); both are key events in the pathogenesis of pulmonary
fibrosis (Horowitz et al., 2007; Tseng et al., 2013; Kasabova et al.,
2014; Deng et al., 2015). These TGF-β1-mediated events are
known to be mediated through distinct signaling pathways,
such as mitogen-activated protein kinases (MAPKs) and Smad
3 (Horowitz et al., 2007; Tseng et al., 2013; Kasabova et al.,
2014; Deng et al., 2015; Sato et al., 2016). The pathogenesis of
pulmonary fibrosis has been widely studied, but the search for
therapeutic interventions remains challenging (Wuyts et al.,
2013).
Paeonol (2′-hydroxy-4′-methoxyacetophenone), the main
phenolic compound of the radix of the Chinese herb Paeonia
suffruticosa (Cortex Moutan), has been used as a traditional
herbal medicine for thousands of years (Zhang et al., 1996;
Matsuda et al., 2001). Paeonol has been demonstrated to have
antioxidant activity when used in ex vitro (Zhang et al., 1999;
Matsuda et al., 2001; Jin et al., 2016), in vitro (Tseng et al.,
2012; Liu et al., 2014; Ping et al., 2014), and in vivo preparations
(Hsieh et al., 2006; Liu et al., 2014; Ding et al., 2016; Jin et al.,
2016). Paeonol also has anti-inflammatory actions in a number of
animal models of diseases other than pulmonary fibrosis (Chou,
2003; Du et al., 2010; Fu et al., 2012; Zhao et al., 2013; Chen et al.,
2014; Liu et al., 2014; Ding et al., 2016; Zong et al., 2017) and in
various cell types in response to stimuli (Nizamutdinova et al.,
2007; Chae et al., 2009; Du et al., 2010; Himaya et al., 2012; Tseng
et al., 2012; Kong et al., 2013; Liu et al., 2014; He et al., 2016;
Jin et al., 2016). Thus, the antioxidant and anti-inflammatory
properties of paeonol make it a potential drug for the therapy of
pulmonary fibrosis. However, this potential remains to be proven.
We aimed to investigate the therapeutic effects of paeonol on
pulmonary inflammation and fibrosis in vivo and to determine
any therapeutic mechanism underlying the beneficial effects of
paeonol in vitro. We used a murine model with bleomycin
insult (Chua et al., 2005; Della Latta et al., 2015) to assess the
inhibitory effects of paeonol on various indices of oxidative
stress, inflammation, and fibrosis in the lungs. Additionally, we
used an established in vitro model of lung fibroblasts (Tseng
et al., 2013; Kasabova et al., 2014) to determine the suppressive
effects of paeonol on the TGF-β1-mediated activation of the
MAPKs/Smad3 signaling pathway and on the increase in fibrotic
responses.
METHODS
Reagents
Antibodies (Abs) to measure α-SMA, type 1α1 collagen
(COL1A1), Jun N-terminal kinase (JNK), p38, Smad3, phospho-
JNK, phospho-p38, and phospho-Smad3 were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Sircol Collagen Assay kit was purchased from Biocolor Ltd.
(Carrickfergus, UK). ELISA kit used to measure TGF-β1
was purchased from Enzo Life Sciences (Farmingdale, NY,
USA). Rabbit antibody against 4-hydroxynonenal (4-HNE)
was purchased from Abcam (Cambridge, MA, USA). Mouse
antibody against α-tubulin, paeonol (purity > 99%, HPLC),
N-acetyl-cysteine, SIS3, Masson’s trichrome stain kit, and
malondialdehyde (MDA) kit were purchased from Sigma-
Aldrich (St. Louis, MO, USA). SB203580, SP600125, and
PD98059 were obtained from Calbiochem (San Diego, CA,
USA). Bleomycin was purchased from Nippon Kayaku (Tokyo,
Japan).
Murine Model of Pulmonary Fibrosis and
Paeonol Treatment
All animal experiments were approved by the Animal Care
and Use Committee of the National Yang-Ming University.
Eight-week old C57BL/6J mice (National Laboratory Animal
Center, Taipei, Taiwan) were randomly divided into four
experimental groups: Control (PBS, the vehicle of bleomycin)
group, PBS+paeonol group, bleomycin+saline group (saline,
the vehicle of paeonol), and bleomycin+paeonol group. To
induce pulmonary fibrosis, mice were treated with a single
sublethal dose of bleomycin (3 mg/kg) via intratracheal infusion.
For the PBS groups, the same protocol was conducted, but
instead of bleomycin, the mice received the same volume of
intratracheal PBS. For the therapeutic treatment, mice received
daily treatment with paeonol (10 mg/kg) or saline by gastric
gavage for 21 days. Animals in each group were euthanized
21 days after intratracheal bleomycin administration. The dose
of daily treatment with paeonol was adopted from our recent
study (Liu et al., 2014). The dose of bleomycin and protocol of
the induction of pulmonary fibrosis were adopted from a study
reported previously (Izbicki et al., 2002).
Preparation of Bronchoalveolar Lavage
Fluid (BALF) and Lung Tissues
At the end of each experiment, the mice were euthanized with
CO2, and a middle thoracotomy was performed. The left lung
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was ligated, and the right lung was lavaged four times with
0.4 ml warm PBS containing a complete protease inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany). The BALF
samples were then centrifuged at 350 × g for 5 min at 4◦C,
and the supernatant of the first lavage fluid was stored at
−80◦C for analysis of total protein using Bio-Rad protein assay
reagent (Bio-Rad Laboratories, Hercules, CA, USA). The cell
pellets of the BALF samples were re-suspended in PBS for
cell counting. Furthermore, the right lung was then stored at
−80◦C for subsequent analysis. The left lung was fixed with 4%
paraformaldehyde and embedded in paraffin.
Histological Assessment
Formalin-fixed, paraffin-embedded tissue blocks were cut into 8-
µm sections. Sections were deparaffinized, rehydrated, and then
subjected to hematoxylin and eosin (H&E) staining andMasson’s
trichrome staining to investigate levels of lung inflammation
and collagen deposition. These sections were viewed under a
microscope (Motic TYPE 102M, Xiamen, China).
Measurement of Indices of Pulmonary
Fibrosis
The concentrations of TGF-β1 and the total collagen in the lung
tissue samples were measured using ELISA kits and the Sircol
Collagen Assay kit, respectively, according to the manufacturer’s
instructions. In addition, the lung tissue samples were lysed
with phosphate buffered saline containing 1% Triton X-100,
0.1% SDS, 0.5% sodium deoxycholate, 1 µg/mL leupeptin, 10
µg/mL aprotinin, 1 mM PMSF, Tyr phosphatase cocktail I and
Ser/Thr phosphatase cocktail II on ice. Tissue extracts underwent
centrifugation at 12,000 × g for 5 min at 4◦C, and supernatants
were collected as tissue lysates. The tissue lysates were used
to measure the level of α-SMA and COL1A1 by Western blot
analysis.
Measurement of Indices of Oxidative
Stress
Levels of MDA and 4-HNE in the lung tissue samples were
measured by assay kits and Western blot analysis, respectively.
The levels of these two products of lipid peroxidation were used
to reflect the levels of oxidative stress (Li et al., 2015; Yoon et al.,
2016).
Cell Culture
Human fetal lung fibroblasts (HFL-1) were purchased from
TaiwanMedical Cell andMicrobial Resources (Hsinchu, Taiwan).
Lung fibroblasts were cultured in F12K medium containing 10%
fetal bovine serum (FBS), 1× low serum growth supplement,
100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL
amphotericin B (Biological Industries, Kibbutz Beit Haemek,
Israel) at 37◦C in an incubator supplied with 5% CO2.When the
cells reached 80% confluence, they were stimulated by human
recombinant TGF-β1 (0–5 ng/ml) with or without paeonol
treatment (0–0.4 mM). The concentration of TGF-β1 (Kasabova
et al., 2014) and paeonol (Liu et al., 2014) were adopted from
studies reported previously.
Western Blot Analysis
The cell lysates were prepared using cell lysis buffer (Cell
Signaling, Beverly, MA, USA). Aliquots of cell lysates
or tissue lysates were separated by 8–12% SDS-PAGE
and then transblotted onto ImmobilonTM-P membrane
(Millipore). After being blocked with 5% skim milk, the
blots were incubated with various primary antibodies and
then appropriate secondary antibodies. The specific protein
bands were detected using an enhanced chemiluminescence kit
(Perkin-Elmer), which was followed by the quantification using
ImageQuant 5.2 software (Healthcare Bio-Sciences, Philadelphia,
PA, USA).
Statistical Analysis
The results are presented as mean ± SEM. Statistical evaluations
involved one-way ANOVA followed by Dunnett’s test or Fisher’s
least significant difference procedure for multiple comparisons as
appropriate. Differences were considered statistically significant
at p< 0.05.
RESULTS
Effect of Paeonol on Pathological
Manifestations in the Mouse Lung
Twenty one days after bleomycin administration, mice showed
both inflammation and fibrosis in the lungs. When compared
to the PBS control mice, bleomycin produced pathological
manifestations, including increased number of pulmonary
interstitial cells (e.g., inflammatory cells and fibroblasts),
thickening of the alveolar walls, focal regions of damaged
alveolar structure, granulomatous lesions in the alveolar
space, and distorted pulmonary architecture, as evidenced
by the histological evaluation of the H&E stained lung
sections (Figure 1A). Additionally, mice challenged with
bleomycin showed notable deposition of collagen in the
pulmonary interstitium, as indicated by Masson’s trichrome
staining (Figure 1B). Importantly, all these pathological
manifestations were largely alleviated in the bleomycin-insulted
mice that underwent paeonol treatment (Figures 1A,B).
These pathological manifestations were not found in
the PBS-insulted mice that underwent paeonol treatment
(Figures 1A,B).
Effect of Paeonol on Indices of
Inflammation, Fibrosis, and Oxidative
Stress in the Mouse Lung
Compared with the PBS control mice, mice with intratracheal
bleomycin showed an increase in total cell count (Figure 2A),
differential cell count (Figure 2B), and total protein
concentrations in BALF (Figure 2C), all of which are indices
of pulmonary inflammation. Additionally, bleomycin-insulted
mice showed increased lung levels of TGF-β1 (Figure 3A)
and total collagen concentration (Figure 3B), as measured by
ELISA, and increased lung expression of COL1A1 (Figure 3C)
and α-SMA (Figure 3D), as assessed by Sircol Collagen
Assay kit or Western blot analysis; all these are indices of
Frontiers in Physiology | www.frontiersin.org 3 March 2017 | Volume 8 | Article 193
Liu et al. Paeonol Inhibits Bleomycin-Induced Pulmonary Fibrosis
FIGURE 1 | Representative images of H&E stained (A) and Masson’s trichrome (B) lung sections obtained from mice of 4 study groups. Mice were intratracheally
infused with either PBS or a single sublethal dose of bleomycin (3 mg/kg). Mice also received daily treatment with paeonol (10 mg/kg; Pae) or saline (Sal.) by gastric
gavage for 21 days. Lung tissues were obtained 21 days after bleomycin treatment. The magnification is 200X for each panel. Note that bleomycin resulted in
extensive infiltration of inflammatory cells (A) and collagen deposition, as indicated by the blue color (B). These signs of pulmonary inflammation and fibrosis were
markedly alleviated by paeonol treatment.
FIGURE 2 | Treatment with paeonol (Pae) alleviates bleomycin (BLM)-induced increase in indices of pulmonary inflammation in mice. The indices
measured were total cell count (A), differential cell count (B), and total protein concentration (C) in bronchoalveolar lavage fluid (BALF) sampled from mice of 4 study
groups. Data in each group are mean ± SEM from 6 mice. *p < 0.05 vs. the PBS group; #p < 0.05 vs. the BLM group. See legend of Figure 1 for treatments of 4
study groups. See the legend of Figure 1 for detailed information on each study group.
pulmonary fibrosis. Furthermore, bleomycin-insulted mice
showed an increase in lung levels of MDA (Figure 4A), as
measured by ELISA and 4-HNE (Figure 4B), as assessed
by Western blot analysis; all these are indices of pulmonary
oxidative stress. Importantly, all these pathophysiological
indices were significantly reduced in the bleomycin-insulted
mice that underwent paeonol treatment (Figures 2–4).
These pathophysiological indices did not increase in mice
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FIGURE 3 | Treatment with paeonol (Pae) alleviates bleomycin (BLM)-induced increases in indices of pulmonary fibrosis in mice. The indices measured
were levels of transforming growth factor-β1 (A; TGF-β1), total collagen (B), type 1α1 collagen (C; COL1A1), and α-smooth muscle actin (D; α-SMA) in lung tissues
sampled from mice of 4 study groups. Data in (A,B) were measured by ELISA. Data in (C,D) were measured by Western blot analysis. Data in each group are mean ±
SEM from 6 mice. *p < 0.05 vs. the PBS group; #p < 0.05 vs. the BLM group.
FIGURE 4 | Treatment with paeonol (Pae) alleviates bleomycin (BLM)-induced increase in indices of pulmonary oxidative stress in mice. The indices
measured were levels of malondialdehyde (MDA, A) and 4-hydroxynonenal modified proteins (4-HNE, B) in lung tissues sampled from mice belonging to four study
groups. Data in (A) were measured by an assay kit, whereas data in (B) were measured by Western blot analysis. Data in each group are mean ± SEM from 6 mice.
*p < 0.05 vs. the PBS group; #p < 0.05 vs. the BLM group.
Frontiers in Physiology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 193
Liu et al. Paeonol Inhibits Bleomycin-Induced Pulmonary Fibrosis
subjected to PBS insult and underwent paeonol treatment
(Figures 2–4).
Effect of Paeonol on the TGF-β1-Mediated
Induction of α-SMA and Type 1α1 Collagen
in Lung Fibroblasts
We used TGF-β1-stimulated human lung fibroblasts as an in
vitro model to study the therapeutic mechanism of paeonol.
Exposure of lung fibroblasts to 0–5 ng/ml TGF-β1 for 24 h
induced a concentration-dependent increase in expression of α-
SMA (Figure 5A). Pretreatment with various concentrations of
paeonol (0, 0.1, 0.2, and 0.4 mM) concentration-dependently
attenuated the induction of α-SMA (Figure 5B) and COL1A1
(Figure 5C) by TGF-β1, whereas pretreatment with paeonol in
lung fibroblasts without TGF-β1 stimulation failed to alter the
expression of α-SMA and COL1A1 (Figures 5B,C). Based on the
abovementioned result, we used 5 ng/ml TGF-β1 and 0.4 mM
paeonol as the standard stimulus and treatment, respectively,
for the subsequent experiments. Exposure to bleomycin did not
alter expression of a-SMA and type COL1A1 in human lung
fibroblasts (Supplemental Material).
Effect of Paeonol on the TGF-β1-Mediated
Activation of MAPKs/Smad3 Signaling in
Lung Fibroblasts
Activation of MAPKs and Smad3 is known to be important
in inducing fibrotic responses to TGF-β1 in lung fibroblasts
(Horowitz et al., 2007; Tseng et al., 2013; Kasabova et al., 2014;
Deng et al., 2015). Using various pharmacological inhibitors,
we found that exposure of lung fibroblasts to 5 ng/ml TGF-
β1 for 24 h produced induction of α-SMA or COL1A1,
both of which were inhibited by pretreatment with either a
JNK inhibitor (SP600125), a p38 inhibitor (SB203580), or a
Smad3 inhibitor (SIS3), but were unaffected by pretreatment
with an ERK inhibitor (PD98059) (Figure 6). These results
suggest the important roles of JNK and p-38 (two members
of MAPKs), and Smad3 (a transcription factor) in these TGF-
β1-mediated fibrotic responses. Additionally, we found that,
relative to the control group, exposure of lung fibroblasts
to 5 ng/ml TGF-β1 for 1 h indeed increased the amount
of phosphorylated JNK (Figure 7A), phosphorylated p-38
(Figure 7B), and phosphorylated Smad3 (Figure 7C). Such TGF-
β1-induced activation of the MAPKs/Smad3 signaling was
significantly attenuated by pretreatment with 0.4 mM paeonol
FIGURE 5 | Treatment with paeonol (Pae) inhibits TGF-β1-induced increases in expression of α-smooth muscle actin (α-SMA) and type 1α1 collagen
(COL1A1) in human lung fibroblasts. In (A), stimulatory effects of different concentrations of TGF-β1 (0–5 ng/ml) on α-SMA were studied. In (B,C), the suppressive
effects of Pae (0–0.4 mM) on TGF-β1 (5 ng/ml)-induced α-SMA and COL1A1 were studied. Protein samples were harvested 24 h after treatments and data were
measured by Western blot analysis. Data in each group are mean ± SEM from 4 independent experiments. *p < 0.05 vs. the control group; #p < 0.05 vs. the
TGF-β1 group without Pae treatment.
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FIGURE 6 | Suppressive effects of various pharmacological inhibitors on TGF-β1-induced increases in expression of α-smooth muscle actin (α-SMA)
and type 1α1 collagen (COL1A1) in human lung fibroblasts. The inhibitors (Inhib.) used were JNK inhibitor (A; SP600125, 10 µM), p38 inhibitor (B; SB203580,
10 µM), Smad3 inhibitor (C; SIS3, 3 µM), and ERK inhibitor (D; PD98059, 10 µM). Group data of expression of α-SMA and COL1A1 are shown in (E,F). Protein
samples were harvested 24 h after treatments and data were measured by Western blot analysis. Data in each group are mean ± SEM from 4 independent
experiments. Note that only PD98059 had no significant effect (p > 0.05) on TGF-β1-induced increase in expression of α-SMA and COL1A1.
(Figure 7). Pretreatment with paeonol in lung fibroblasts without
TGF-β1 stimulation failed to alter the expression of these
signaling proteins (Figure 7). Our results thus established the
relationship between phosphorylations of MAPKs or Smad3 and
α-SMA or COL1A1.
DISCUSSION
Our in vivo study demonstrates clearly that 21 days after the
insult, bleomycin caused pulmonary inflammation and fibrosis,
as evidenced by lung histopathological manifestations and
increase in various indices. The inflammatory indices measured
were total cell count, differential cell count, and total protein
concentration in BALF. The fibrotic indices measured were lung
levels of TGF-β1 (a potent profibrogenic cytokine), total collagen,
COL1A1, and α-SMA (a marker of myofibroblasts). Bleomycin
also increased oxidative stress, as reflected by increased levels
of MDA and 4-HNE in the lungs. All these pathophysiological
events were suppressed by daily treatment with paeonol,
suggesting that paeonol has antioxidant, anti-inflammatory, and
anti-fibrotic functions against bleomycin-induced pulmonary
fibrosis in mice. Our in vitro study demonstrated that exposure
of lung fibroblasts to TGF-β1 increased the production of α-
SMA and COL1A1, both of which were inhibited by inhibitors
of JNK, p38, and Smad3. The important roles of these signaling
proteins gain support from our observations, revealing that TGF-
β1 exposure indeed increased their phosphorylated amount prior
to the induction of α-SMA and COL1A1. Notably, all these
TGF-β1-induced cellular events were suppressed by paeonol
treatment, thereby indicating that the beneficial effect of paeonol
may be, at least in part, mediated through the inhibition of the
MAPKs/Smad3 signaling.
Our study appears to be the first to report that paeonol
has antioxidant, anti-inflammatory, and anti-fibrotic activities
against bleomycin-induced pulmonary fibrosis. Paeonol has been
reported to possesses antioxidant activity against oxidative stress
ex vitro (Zhang et al., 1999; Matsuda et al., 2001; Jin et al., 2016),
in vivo (Hsieh et al., 2006; Liu et al., 2014; Ding et al., 2016), and
in vitro (Tseng et al., 2012; Liu et al., 2014; Ping et al., 2014).
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FIGURE 7 | Treatment with paeonol (Pae) inhibits TGF-β1-induced increases in phosphorylation of JNK (A), p38 (B), and Smad3 (C) in human lung
fibroblasts. Pae (0.4 mM) was used to suppress TGF-β1 (5 ng/ml)-induced increases in phosphorylation. Protein samples were harvested 1 h after treatment. Levels of
phospho- (p-) and total- (t-) proteins were measured by Western blot analysis. Data in each group are mean ± SEM from 4 independent experiments. *p < 0.05 vs.
the control group; #p < 0.05 vs. the TGF-β1 group.
Paeonol suppressed the inflammation in the lungs with cigarette
smoke exposure (Liu et al., 2014), acetaminophen-induced liver
injury (Ding et al., 2016), drug-induced colitis (Jin et al., 2016;
Zong et al., 2017), ischemia-reperfusion brain injury (Hsieh
et al., 2006), lipopolysaccharide-induced lung injury (Fu et al.,
2012; Chen et al., 2014), ovalbumin-induced hyperresponsive
airways (Du et al., 2010), atherosclerosis (Zhao et al., 2013),
and carrageenan-evoked thermal hyperalgesia (Chou, 2003) in
several animal models. Paeonol has been demonstrated to inhibit
the inflammatory responses in cigarette smoke-stimulated lung
epithelial cells (Liu et al., 2014), in lipopolysaccharide-stimulated
macrophages (Chae et al., 2009; Himaya et al., 2012; Chen et al.,
2014; Jin et al., 2016), in microglial cells (Himaya et al., 2012;
Tseng et al., 2012; He et al., 2016), and in TNF-α-stimulated
endothelial cells (Nizamutdinova et al., 2007). Particularly, the
anti-inflammatory effect of paeonol in vitro appears to be due to
inactivation of the signaling pathways involved (Nizamutdinova
et al., 2007; Chae et al., 2009; Himaya et al., 2012; Tseng et al.,
2012; Chen et al., 2014; Liu et al., 2014; Jin et al., 2016).
Only one study reported the therapeutic effect of paeonol on
carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting
activation of hepatic stellate cells (Kong et al., 2013). Thus,
our findings are in good agreement with the abovementioned
observations. In this study, we measured in vivo responses 21
days after bleomycin administration, a duration that allowed
us to observe both inflammatory and fibrotic responses, as
reported previously (Izbicki et al., 2002; Della Latta et al.,
2015). All these bleomycin-induced pathophysiological events
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are similar to those described previously (Izbicki et al., 2002;
Chua et al., 2005; Li et al., 2015). Particularly, macrophages were
the predominant cells in the inflammatory cell infiltration at
21 days after bleomycin insult, a finding that is consistent with
those reported previously (Izbicki et al., 2002). This experimental
model has been widely used to investigate on the pathogenesis
and potential therapies of pulmonary fibrosis (Chua et al., 2005;
Della Latta et al., 2015). In this model, bleomycin causes oxidative
lung injury and this leads to lung inflammation, which in turn
promotes various lung fibrotic responses (Chua et al., 2005;
Hecker et al., 2009; Della Latta et al., 2015). Since paeonol
was found to effectively reduce the lung oxidative stress in our
model, one possible therapeutic mechanism is the suppression
of oxidative lung injury, which would alleviate the subsequent
inflammatory and fibrotic events. Also, pulmonary responses
of oxidative stress and inflammation induced by bleomycin are
interrelated and this suggests that suppression of one response
may lead to inhibition of the other. The bleomycin-induced lung
oxidative stress has been suggested to be a result from activation
of NADPH oxidases and/or imbalance between oxidation and
anti-oxidation capacity (Cheresh et al., 2013). Additionally, our
in vitro findings regarding the TGF-β1-induced activation of
the MAPKs/Smad3 signaling and productions of α-SMA and
COL1A1 in lung fibroblasts are in agreement with observations
reported by other investigators (Horowitz et al., 2007: Kasabova
et al., 2014; Tseng et al., 2013; Deng et al., 2015). Previous
investigations have shown that the TGF-β1-induced activation
of p38 and Smad3 and, fibrotic responses in fibroblasts are
mediated through the generation of reactive oxygen species
(Alili et al., 2014; Sato et al., 2016). Thus, the same antioxidant
function of paeonol can also explain our in vitro findings. The
other possible therapeutic mechanism is that paeonol directly
suppresses lung inflammation and fibrosis by inhibiting related
signaling pathways. In fact, the biological activities of paeonol are
known to be largely related to its ability to modulate associated
signaling pathways (Tang et al., 2016). In our in vivo study,
we speculate that the target cells for paeonol may include all
types of cells that participate in the development of lung fibrosis,
such as lung epithelial cells, endothelial cells, fibroblasts, and
myofibroblasts.
In our in vivo study, the dose of paeonol (10 mg/kg) used
is only one tenth of the dose used in previous studies in mice
(Du et al., 2010; Zhao et al., 2013; Ding et al., 2016) and
was chosen to avoid possible adverse effects. In our recent
study (Liu et al., 2014), mice seemed to be well tolerated with
daily treatment with the same dose for 28 days. Paeonol has
a minimal systemic toxicity (LD50 = 3430 mg/kg) when orally
administered to mice (Zhang et al., 1996). The in vivo dose of
paeonol we used is far less than the LD50 dose; thus, we did
not evaluate the toxicity of this drug. In our in vitro study,
the concentration of paeonol (0.4 mM) did not produce any
notable cytotoxicity. This concentration of paeonol was found to
have no effect on the viability of lung epithelial cells (Liu et al.,
2014) and macrophages (Ping et al., 2014). The Chinese herb P.
suffruticosa has therapeutic effects, such as sedation, hypnosis,
antipyresis, analgesic, anti-inflammation, and immunoregulation
in human (Zhang et al., 1996). Although extensive studies
have been conducted to investigate the beneficial effects of
paeonol in several animal models of diseases, investigation
on its clinical use as a single compound appears to be
limited.
In summary, our findings suggest a novel role for paeonol
regarding the alleviation of oxidative stress, inflammation, and
fibrosis in the lungs induced by bleomycin in vivo and the
suppression of the TGF-β1-induced fibrotic responses in vitro
by inhibiting MAPKs/Smad3 signaling. While several drugs have
been proposed for the treatment of pulmonary fibrosis (Moeller
et al., 2008), our findings support the notion that paeonol can
potentially be used as a treatment for this disease.
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